Publication details
Co napověděly výsledky posledních studií systémové léčby metastatického kolorektálního karcinomu a jaký zvolit postup v dalších liniích systémové léčby
| Title in English | What the results of latest studies of systemic treatment of metastatic colorectal carcinoma suggest and what procedures to choose in further lines of systemic treatment |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | colorectal cancer; second line of treatment; evacizumab; aflibercept; cetuximab; panitumumab; regorafenib |
| Description | Colorectal cancer remains a major health problem in Czech Republic. Most of the colorectal cancer patients eventually develop a metastatic disease. Overall therapeutic aims are to control the disease, prolong survival and maximise life quality. The choice of the first line therapy affects the options for second line treatment. The combination of a fluoropyrimidine with irinotecan or oxaliplatin is the standard chemotherapy for the first and second line treatment. Targeted treatment includes an antiangiogenic drug bevacizumab and aflibercept, EGFR inhibitors cetuximab and panitumumab, and multikinase inhibitor regorafenib. Efficacy and treatment toxicity are important factors in choosing among treatment options. |